Market Place
Sourcing Support
BioNxt Files Patents for Sublingual Anticancer Drugs in Australia
29 Oct 2024 //
ACCESSWIRE
Terry Lynch Joins BioNxt as Capital Markets Advisor.
07 Oct 2024 //
ACCESSWIRE
BioNxt Signs Statement For Cladribine ODF Development With CRO
17 Jul 2024 //
ACCESSWIRE
BioNxt Signs Master Agreement With Int`l Contract Research & Manufacturing Org
08 Jul 2024 //
ACCESSWIRE
BioNxt Closes Second Tranche Of Private Placement
19 Jun 2024 //
ACCESSWIRE
BioNxt Solutions Announces ODF Cladribine Update and Financing
25 Apr 2024 //
ACCESSWIRE
BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps
18 Mar 2024 //
ACCESSWIRE
BioNxt Reports Successful Results From ODF Cladribine PK Study
13 Mar 2024 //
ACCESSWIRE
BioNxt Reports Completion of ODF Cladribine PK Study
04 Mar 2024 //
ACCESSWIRE
BioNxt Reports Completion of ODF Cladribine PK Study
01 Mar 2024 //
ACCESSWIRE
BioNxt Solutions Finalizes Agreement
16 Feb 2024 //
ACCESSWIRE
BioNxt Reports Successful Results From ODF Cladribine Toxicity Study
07 Feb 2024 //
ACCESSWIRE
BioNxt Announces Closing of Final Tranche of Non-Brokered Private Placement
29 Jan 2024 //
ACCESSWIRE
BioNxt Announces Completion of Cladribine ODF Toxicity Study and Financing
21 Dec 2023 //
ACCESSWIRE
BioNxt Receives Delivery of Premium Commercial Coating
12 Dec 2023 //
ACCESSWIRE
BioNxt Solutions Announces Completion of Debenture and Interest Settlement
08 Dec 2023 //
ACCESSWIRE
Bionxt Solutions Announces Convertible Debenture and Interest Settlement
24 Nov 2023 //
ACCESSWIRE
BioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy
20 Nov 2023 //
ACCESSWIRE
BioNxt Reports on New Cladrabine ODF Product Development
15 Nov 2023 //
ACCESSWIRE
BioNxt Signs Agreement For 100% Acquisition of IP & Co-Development of Cladribine
13 Nov 2023 //
ACCESSWIRE
BioNxt Solutions Reports on Barcelona CPHI Conference
06 Nov 2023 //
ACCESSWIRE
BioNxt Solutions Announces Closing of Third & Final Tranche of Private Placement
27 Oct 2023 //
ACCESSWIRE
BioNxt Solutions Announces Change of Directors
03 Oct 2023 //
ACCESSWIRE
Bionxt Announces Closing of Second Tranche of Non-Brokered Private Placement
28 Sep 2023 //
ACCESSWIRE
Bionxt Solutions Announces Closing of First Tranche of Non-Brokered Placement
28 Aug 2023 //
ACCESSWIRE
BioNxt Solutions Announces Non-Brokered Private Placement
04 Aug 2023 //
ACCESSWIRE
BioNxt Signs LOI for Acquisition of IP & Development of ODF Drug Reformulation
02 Aug 2023 //
ACCESSWIRE
BioNxt Receives Approval for European Clinical Study of Transdermal Rotigotine
15 May 2023 //
ACCESSWIRE
BioNxt Successfully Completes Pilot Study for Contract Development Customer
09 May 2023 //
ACCESSWIRE
BioNxt Secures Contract to Develop and Manufacture ODF Product
24 Apr 2023 //
ACCESSWIRE
BioNxt Acquires Commercial Coating & Cutting to Build Out EC MFG Capacity
17 Apr 2023 //
ACCESSWIRE
BioNxt Reports on Enteric Coating Drug Delivery Program
14 Apr 2023 //
ACCESSWIRE
BioNxt Announces Closing of Non-Brokered Private Placement
03 Apr 2023 //
ACCESSWIRE
BioNxt Solutions Closes First Tranche of Financing
27 Mar 2023 //
ACCESSWIRE
Bionxt Solutions Announces Non-Brokered Private Placement
10 Mar 2023 //
ACCESSWIRE
BioNxt Solutions Acquires Novel Precision Drug Coating and Delivery Technology
07 Mar 2023 //
ACCESSWIRE
BioNxt Announces Engagement Of Canaccord For Early Warrant Exercise Program
02 Mar 2023 //
ACCESSWIRE
BioNxt Begins Drug Absorption Study for Transdermal Rotigotine Patch
02 Mar 2023 //
CONTRACT PHARMA
BioNxt Commences Manufacture of Sample for Study of Transdermal Rotigotine Patch
01 Mar 2023 //
ACCESSWIRE
